When Waldenström macroglobulinemia hits the kidney: Description of a case series and management of a "rare in rare" scenario.
Waldenström macroglobulinemia
amyloidosis
kidney disease
lymphoma
lymphoproliferative disorders
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
revised:
29
02
2024
received:
23
10
2023
accepted:
09
03
2024
medline:
25
4
2024
pubmed:
25
4
2024
entrez:
25
4
2024
Statut:
ppublish
Résumé
Renal injury related to Waldenström macroglobulinemia (WM) occurs in approximately 3% of patients. Kidney biopsy is crucial to discriminate between distinct histopathological entities such as glomerular (amyloidotic and non-amyloidotic), tubulo-interstitial and non-paraprotein mediated renal damage. In this context, disease characterization, management, relationship between renal, and hematological response have been poorly explored. We collected clinical, genetic and laboratory data of seven cases of biopsy-proven renal involvement by WM managed at our academic center and focused on three cases we judged paradigmatic discussing their histopathological patterns, clinical features, and therapeutic options. In this illustrative case series, we confirm that serum creatinine levels and 24 h proteinuria are parameters that when altered should prompt the clinical suspicion of WM-related renal involvement, even if at present there are not precise cut-off levels recommending the execution of a renal biopsy. In our series AL Amyloidosis (n = 3/7) and tubulo-interstitial infiltration by lymphoma cells (n = 3/7) were the two more represented entities. BTKi did not seem to improve renal function (Case 1), while bortezomib-based regimens demonstrated a beneficial activity on the hematological and organ response, even when used as second-line therapy after chemoimmunotherapy (Case 3) and also with coexistence of anti-MAG neuropathy (Case 2). In case of poor response to bortezomib, standard chemoimmunotherapy (CIT), such as rituximab-bendamustine, represents an effective option (Case 1, 6, and 7). In our series, CIT generates durable responses more frequently in cases with amyloidogenic renal damage (Case 1, 5, and 7). In this illustrative case series, we confirm that serum creatinine levels and 24 h proteinuria are parameters that when altered should prompt the clinical suspicion of WM-related renal involvement, even if at present there are not precise cut-off levels recommending the execution of a renal biopsy. Studies with higher numerosity are needed to better clarify the pathological and clinical features of renal involvement during WM and to determine the potential benefit of different therapeutic regimens according to the histopathological subtypes.
Sections du résumé
BACKGROUND
BACKGROUND
Renal injury related to Waldenström macroglobulinemia (WM) occurs in approximately 3% of patients. Kidney biopsy is crucial to discriminate between distinct histopathological entities such as glomerular (amyloidotic and non-amyloidotic), tubulo-interstitial and non-paraprotein mediated renal damage. In this context, disease characterization, management, relationship between renal, and hematological response have been poorly explored. We collected clinical, genetic and laboratory data of seven cases of biopsy-proven renal involvement by WM managed at our academic center and focused on three cases we judged paradigmatic discussing their histopathological patterns, clinical features, and therapeutic options.
CASE
METHODS
In this illustrative case series, we confirm that serum creatinine levels and 24 h proteinuria are parameters that when altered should prompt the clinical suspicion of WM-related renal involvement, even if at present there are not precise cut-off levels recommending the execution of a renal biopsy. In our series AL Amyloidosis (n = 3/7) and tubulo-interstitial infiltration by lymphoma cells (n = 3/7) were the two more represented entities. BTKi did not seem to improve renal function (Case 1), while bortezomib-based regimens demonstrated a beneficial activity on the hematological and organ response, even when used as second-line therapy after chemoimmunotherapy (Case 3) and also with coexistence of anti-MAG neuropathy (Case 2). In case of poor response to bortezomib, standard chemoimmunotherapy (CIT), such as rituximab-bendamustine, represents an effective option (Case 1, 6, and 7). In our series, CIT generates durable responses more frequently in cases with amyloidogenic renal damage (Case 1, 5, and 7).
CONCLUSION
CONCLUSIONS
In this illustrative case series, we confirm that serum creatinine levels and 24 h proteinuria are parameters that when altered should prompt the clinical suspicion of WM-related renal involvement, even if at present there are not precise cut-off levels recommending the execution of a renal biopsy. Studies with higher numerosity are needed to better clarify the pathological and clinical features of renal involvement during WM and to determine the potential benefit of different therapeutic regimens according to the histopathological subtypes.
Substances chimiques
Bortezomib
69G8BD63PP
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2062Informations de copyright
© 2024 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720‐1748.
Vos JM, Gustine J, Rennke HG, et al. Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes. Br J Haematol. 2016;175(4):623‐630.
Higgins L, Nasr SH, Said SM, et al. Kidney involvement of patients with Waldenström macroglobulinemia and other IgM‐producing B cell lymphoproliferative disorders. Clin J Am Soc Nephrol. 2018;13(7):1037‐1046.
Danesin N, Lo Schirico M, Scapinello G, et al. Waldenström macroglobulinemia in very elderly (≥75‐year‐old) patients: a 33‐year‐retrospective cohort study in an Italian university hospital. HemaSphere. 2023;7(10):e964.
Castillo JJ, Callander NS, Baljevic M, Sborov DW, Kumar S. The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. Am J Hematol. 2021;96(7):846‐853.
Uppal NN, Monga D, Vernace MA, et al. Kidney diseases associated with Waldenström macroglobulinemia. Nephrol Dial Transplant. 2019;34(10):1644‐1652.
Chauvet S, Bridoux F, Ecotière L, et al. Kidney diseases associated with monoclonal immunoglobulin M‐secreting B‐cell lymphoproliferative disorders: a case series of 35 patients. Am J Kidney Dis. 2015;66(5):756‐767.
Hogan JJ, Alexander MP, Leung N. Dysproteinemia and the kidney: core curriculum 2019. Am J Kidney Dis. 2019;74(6):822‐836.
Törnroth T, Heiro M, Marcussen N, Franssila K. Lymphomas diagnosed by percutaneous kidney biopsy. Am J Kidney Dis. 2003;42(5):960‐971.
Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007;25(22):3344‐3349.
Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first‐line treatment for patients with indolent and mantle‐cell lymphomas: an open‐label, multicentre, randomised, phase 3 non‐inferiority trial. Lancet. 2013;381(9873):1203‐1210.
Hospital MA, Viala K, Dragomir S, et al. Immunotherapy‐based regimen in anti‐MAG neuropathy: results in 45 patients. Haematologica. 2013;98(12):e155‐7.
Gavriatopoulou M, García‐Sanz R, Kastritis E, et al. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow‐up of 6 years. Blood. 2017;129(4):456‐459.
Buske C, Castillo JJ, Abeykoon JP, et al. Report of consensus panel 1 from the 11th international workshop on Waldenstrom's macroglobulinemia on management of symptomatic, treatment‐naïve patients. Semin Hematol. 2023;60(2):73‐79.
D'Sa S, Matous JV, Advani R, et al. Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients. Semin Hematol. 2023;60(2):80‐89.
Abdallah N, Muchtar E, Dispenzieri A, et al. Coagulation abnormalities in light chain amyloidosis. Mayo Clin Proc. 2021;96(2):377‐387.